Which ASX Healthcare Stocks Have Clinical Trials Running in June 2026?

The coming June 2026 will likely prove to be one of the most eventful months ever for ASX healthcare stocks. In fact, there are a number of companies in the process of generating some very exciting real-life clinical events, which could have a significant impact on the share price. Here is a list of current ASX healthcare players actively involved in trials.

Avecho Biotechnology (ASX: AVE) – Phase III CBD Insomnia Trial

Avecho is by far the most pressing topic this month. This Melbourne-headquartered drug delivery technology firm has finished the treatment stage for the last required patient in its pivotal Phase III insomnia trial, with data expected in late June 2026.

In this trial, the drug delivery technology firm is evaluating its TPM-enabled cannabidiol capsule formulation as an insomnia therapy. The interim cohort comprises 244 patients, who have been randomized into three cohorts receiving 150 mg CBD, 75 mg CBD or placebo, respectively, each night.

This trial is an important milestone for the firm, as the interim analysis will give investors their first insight into the drug's efficacy and aid in determining the final sample size required for the trial. 

From a commercial perspective, all bases are covered. Earlier in 2025, Avecho signed a deal with Sandoz AG to license Australian commercial rights, which included an up-front fee of US$3 million, up to US$16 million in milestones and tiered royalties of 14-19% of net sales. 

Thus, a successful interim outcome later this month will provide a huge de-risking event for Avecho and may boost negotiations for commercialization deals elsewhere.

Cynata Therapeutics (ASX: CYP) — Two Key Trials, Both Due This Quarter

Cynata is taking two key clinical data milestones into June quarter, making it an especially eventful biotech stock in the ASX market at the moment.

One such milestone is the phase 2 trial of CYP-001 for acute graft-versus-host disease. It is time that Cynata had marked as the turning point of its clinical development process since the company completed the primary 100-day evaluation of all participants in its Phase 2 trial of CYP-001. The stem cell therapy aims to tackle acute graft-versus-host disease. Now that the primary evaluation period is over, the company will move on to analyze the data, with first data to be released in June 2026.

The trial consisted of a total of 65 subjects recruited from clinical sites in the US, Europe, and Australia. The subjects were then randomized for treatment with steroid therapy alone and with or without CYP-001. 

The medical condition addressed by the drug is very critical. AGVHD is characterized by the destruction of a patient's body tissue by donated immune cells after receiving a bone marrow transplant, which can prove to be deadly for patients.

The second catalyst in the Cynata case study comes from its Phase 3 SCUlpTOR trial in knee osteoarthritis. Cynata revealed that it completed recruitment in the Phase 3 SCUlpTOR trial of its cell therapy product derived from Cymerus called CYP-004 for knee osteoarthritis, with data anticipated to be revealed during the second quarter of 2026. The co-primary endpoints for the study include being in an acceptable knee pain state and MRI-detected cartilage change after 24 months.

It is uncommon for two potential data readouts from the same quarter and the same company to emerge simultaneously.

Dimerix (ASX: DXB) — Phase 3 Kidney Disease Trial IDMC Review

Dimerix is conducting what it calls the only Phase 3 clinical trial in the world specific for focal segmental glomerulosclerosis, an uncommon, progressing disease of the kidneys with no approved drugs.

The upcoming IDMC meeting for the ACTION3 study will be held during the second quarter of 2026 while enrollment and drug administration will go on at the international clinical trial sites.

The statistics of this trial are strong. In a blinded analysis, it was determined that the statistical power of this trial to prove an effect on proteinuria remains greater than 90%.

A total of 333 adult patients have been recruited and dosed for the trial, exceeding the originally set recruitment goal of 286 patients, from 219 sites in 21 different countries including Australia, United States, Europe, and Asia-Pacific areas.

The trial has so far cleared numerous independent safety reviews without requiring any modifications in its protocol. The US FDA has confirmed that proteinuria serves as a good primary endpoint for regulatory approval of the drug.

The safety review by IDMC expected to be conducted this quarter is not the final results release; the trial extends until 2028. However, a clear safety review ensures that the development is going well and takes away all uncertainties from the investors.

Actinogen Medical (ASX: ACW) — Alzheimer's Disease Pivotal Trial

Actinogen is the only ASX-listed company conducting research and development on treatments for Alzheimer’s disease. The XanaMIA trial is the Phase 2b/3 pivotal clinical study of Xanamem, an oral treatment that acts by regulating cortisol levels in brain tissue.

The XanaMIA randomised pivotal clinical trial of Xanamem oral 10mg is on track for top-line data from final analysis at the end of 2026. This trial consists of 247 patients with mild-to-moderate Alzheimer’s disease who will be treated with Xanamem oral 10mg or placebo for 36 weeks, followed by an open-label phase.

Although the trial will not have completed all its analyses by June, it is significant to note that June will still be an important month for Actinogen. An interim analysis on safety and efficacy was performed by an independent Data Monitoring Committee in January 2026, and it recommended proceeding with the trial.

Indeed, just last week, Actinogen was able to add another significant achievement to its portfolio through securing a very positive result in its planned meeting with the European Medicines Agency regarding its scientific advice. Actinogen and the EMA were able to arrive at a mutual understanding of the route needed for market approval of Alzheimer’s disease in Europe. This development, when taken together with previous guidance issued by the FDA, means that Actinogen is now able to pursue a dual-track approach with respect to regulation and trials. The final results will only be known after November 2026, but June is still a busy month.

Why June Matters for ASX Healthcare Investors

ASX biotechs have been lagging behind the rest of the market in recent months as market participants favored cyclicals and resources amid risk-on sentiments. However, the outlook for healthcare in June is particularly eventful compared to other months.

Clinical results updates tend to be inherently binary in nature. Positive results may result in the doubling of a company's share price in a day. Negative results, meanwhile, could destroy years' worth of gains in an instant. The aforementioned stocks all have tangible, upcoming catalysts lined up. These are no mere future catalysts but active trials in their data compilation phases.

For investors who can tolerate greater risks and have a proper appreciation of the clinical programs that are being undertaken, late June 2026 holds significance in terms of the ASX health care companies.

Source : ( Market Analysis )

Note - This article is for informational purposes only and does not constitute financial advice. Clinical trial outcomes are uncertain and investing in early-stage biotech carries significant risk.